Engineered ‘living’ cell implant normalizes blood pressure in mice, study shows

The therapy starts with a sensor that does not look like one at all: a human hormone receptor, embedded in the membrane of an engineered cell, waiting for a blood‑pressure signal to rise.

When that signal — a molecule called angiotensin II — appears in the bloodstream, the cell’s circuitry switches on and quietly releases a countermeasure, a soluble form of the enzyme ACE2 that can neutralize the hormone’s effect. Implanted into hypertensive mice, a cluster of these designer cells pulled blood pressure back to normal and kept it there over the course of the experiment.

The work, described Saturday in the journal Nature Communications, is an early demonstration of what some researchers call autonomous “living medicines.” A team led by synthetic biologist Martin Fussenegger at ETH Zurich and the University of Basel built what they call ARCH, short for “autonomous regulator of chronic hypertension,” and tested it in several mouse models of high blood pressure.

“Capitalizing on a synthetic biology‑inspired engineering approach, we design a fully human, antihypertensive gene circuit called ARCH (autonomous regulator of chronic hypertension), which precisely monitors and efficiently controls angiotensin‑dependent, renin‑angiotensin system (RAS)‑driven hypertension...,” the authors write in the paper’s abstract.

Hypertension, or chronically elevated blood pressure, affects more than 1.3 billion adults worldwide and is a leading driver of heart attacks, strokes and kidney disease. Most patients manage it with daily pills that target the same hormonal system ARCH taps into, the renin‑angiotensin system, which helps regulate blood vessel tone and fluid balance.

ARCH approaches the problem differently. Instead of a drug taken once or twice a day, it is an engineered gene circuit built into human cells, designed to sense when angiotensin II levels go up and respond automatically.

At the heart of the system is the type‑1 angiotensin receptor, or AT1R, a normal human receptor that angiotensin II binds to in order to raise blood pressure. The researchers repurposed AT1R as a molecular sensor: when angiotensin II activates it, that activation is routed to a synthetic promoter — a control switch for genes — that turns on production of a custom‑designed, secreted version of ACE2.

ACE2 is an enzyme that can break down angiotensin II or convert it into peptides that dilate blood vessels. In the ARCH design, the enzyme is engineered for efficient secretion outside the cell, and is referred to as stACE2 in the study. Once released into the circulation, stACE2 reduces the activity of angiotensin II, forming a negative‑feedback loop that is intended to bring blood pressure back toward normal.

Soluble ACE2 itself is not new to medicine: recombinant human soluble ACE2 was explored in small clinical studies during the COVID‑19 pandemic. In ARCH, however, it is produced on demand by implanted cells rather than delivered as an injected drug.

To test whether the circuit works in a living organism, the team loaded the engineered human cells into tiny biocompatible capsules and implanted them into the abdomen of male mice with induced hypertension. Microencapsulation is a common technique meant to protect transplanted cells from the host immune system while still allowing small molecules to pass in and out.

The mice were subjected to at least two forms of high blood pressure. In one set of experiments, the animals received continuous angiotensin II infusions, directly driving up blood pressure. In another, they were fed a high‑fat diet that led to obesity‑associated hypertension and elevated angiotensin II levels.

In both cases, the authors report that the implanted cells were able to sense the excess hormone and counteract it. “Implantation of microencapsulated ARCH‑transgenic human cells into male hypertensive mice restores and maintains normal blood pressure,” the abstract states.

The paper’s figures and supplementary data show that mice carrying ARCH implants returned to blood pressure ranges comparable to healthy controls, while untreated hypertensive mice remained at elevated levels. The study tracked outcomes over short time frames, with some immune profiling and analysis of the capsules performed about two weeks after implantation.

Tolerability in that window appeared acceptable. The researchers collected fluid from the abdominal cavity and profiled immune cells in the area around the implants, using groups of four mice per assay, to look for signs of acute inflammation. They report basic safety and capsule integrity over the two‑week period, but the study does not extend to long‑term performance or late‑emerging side effects.

Many of the animal experiments used small cohorts — often four mice per group — which is typical for early proof‑of‑concept work but limits the strength of any efficacy conclusions. The experiments were conducted in male mice; the paper does not report data from female animals, even though sex differences are known to influence cardiovascular disease.

The authors emphasize that all of the work is preclinical. The cells used are human, but there were no human subjects, and the implants were tested only in mice. The Nature Communications article notes that the manuscript was received on Sept. 1, 2025, and accepted on March 31, 2026, with peer‑review files and source data made available alongside the paper.

If a system like ARCH were ever to move beyond the laboratory, it would face a complex regulatory path. In the United States, a product made of genetically engineered human cells encapsulated in a device and secreting a therapeutic protein would be overseen by the Food and Drug Administration’s Center for Biologics Evaluation and Research as a gene therapy and cellular therapy, and likely as a combination product.

FDA guidance issued in 2020 on “Long Term Follow‑Up After Administration of Human Gene Therapy Products” makes clear that developers of such therapies are generally expected to monitor recipients for years, and in some cases decades, after treatment. The extent of required follow‑up depends on factors such as the kind of genetic vector used, whether it integrates into the recipient’s genome, and how long the engineered cells are expected to survive.

The Nature Communications paper does not fully detail those parameters in a clinical context. It describes the genetic constructs, promoters and plasmids used to assemble the circuit and notes that “all original plasmids used in this study are available from the authors,” but it does not spell out a clinical‑grade manufacturing process or long‑term durability data. Key questions for any future translation include how reliably the circuit can avoid overshooting and causing low blood pressure, whether the capsules can be easily retrieved in an emergency, and whether additional “kill switches” would be built into the cells as a safeguard.

The study also fits into a broader line of work from Fussenegger’s group and other synthetic‑biology labs, which have spent years designing “designer cell” implants that can sense biological signals and secrete hormones, antibodies or other therapeutic molecules in response. ARCH extends that concept to the renin‑angiotensin system, a central regulator of cardiovascular health.

Because hypertension is so common and often poorly controlled, the prospect of an implant that can continuously sense and fine‑tune a patient’s blood pressure is likely to draw interest — and scrutiny. Advanced gene and cell therapies are among the most expensive treatments in medicine today, raising questions about who would have access to complex, one‑time implants if they prove safe and effective.

For now, ARCH remains confined to the laboratory and to mouse models. As a proof of principle, it shows that an engineered gene circuit can use a natural hormone receptor as an input, process that signal, and dispatch a biological countermeasure in real time to normalize blood pressure. Turning that concept into a therapy for people will require much larger animal studies, detailed safety and immunogenicity data, and regulatory answers to how an autonomous “living” device should be monitored — and, if necessary, turned off.